Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Implementation Timeline For Opioid REMS And National Rx Abuse Plan

Date

Action

Aug. 16, 2011

Deadline for affected companies to respond with proposed REMS program.

Early 2012

FDA expects to have all REMS programs approved and all materials agreed upon.

April 2012

Goal for REMS to be fully implemented.

Mid-2012

First opioid REMS assessment is due.

Early 2013

Second opioid assessment due (and annually thereafter).

April 2013

Goal to issue guidance on abuse-deterrent drug formulations and post-market performance assessments.

Goal for passage of legislation requiring prescriber opioid training as part of DEA registration.

April 2014

Goal to have legislation passed in all states establishing prescription drug monitoring programs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel